tm logo
PEMPFIX
Dead/Cancelled
CANCELLED – SECTION 71

on 25 Oct 2024

Last Applicant/ Owned by

E-46012 Valencia

Serial Number

79212465 filed on 02th Jun 2016

Registration Number

5440650 registered on 10th Apr 2018

in the Principal Register

Correspondent Address

Suite 2900

Indianapolis, IN 46282

UNITED STATES

Filing Basis

1. filing basis filed as 66 a

Disclaimer

NO DATA

PEMPFIX

Pharmaceutical and biochemical pharmaceutical preparations for the treatment of or prevention against inflammatory diseases, cancer, infectious diseases, fungal diseases, diseases caused by parasites, eye diseases, diseases of the central and peripheral nervous systems, cardiovascular diseases, diseases affecting the immune system, genetic diseases, single gene disorders, mouth, teeth, skin, hair Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical and biochemical pharmaceutical preparations for the treatment of or prevention against inflammatory diseases, cancer, infectious diseases, fungal diseases, diseases caused by parasites, eye diseases, diseases of the central and peripheral nervous systems, cardiovascular diseases, diseases affecting the immune system, genetic diseases, single gene disorders, mouth, teeth, skin, hair and ear diseases, bone and blood diseases as well as reproductive system diseases; pharmaceutical and biochemical pharmaceutical preparations for contraception; biochemical and chemical pharamceuticals preparations for use with inflammatory diseases, in particular for use with chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against inflammatory diseases, in particular for prevention against chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory skin diseases; biochemical and chemical products for prevention against psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for prevention against blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus diseases; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceuticals preparations for prevention against subepidermal bullous autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoide, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory diseases of the central nervous systems, in particular for prevention against multiple sclerosis; biochemical and chemical pharmaceuticals preparations for the treatment of inflammatory diseases, in particular for the treatment of chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory skin diseases, in particular for the treatment of psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for the treatment of blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus diseases; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceutical preparations for the treatment of subepidermal bullae autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoid, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory diseases of the central nervous system, in particular for the treatment of multiple sclerosis; topical and transdermal pharmaceuticals, in particular creams, dispersions, lotions, ointments, fluids, solutions, sprays, plasters, lacquer and filmforming solutions, for the prevention and treatment of skin diseases of the uppermost skin layer or the upper skin layers; surface treatment pharmaceuticals preparations for use as treatments of immune system diseases, inflammatory diseases, skin, hair and ear diseases; oral administration pharmaceuticals preparations, in particular pills, tablets, lozenges, capsules, liquids, solutions, drops, for the prevention and treatment of central nervous system diseases


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 79212465

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 61459.4002

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

Yes

66A Current

Yes

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
25th Oct 2024CANCELLED SECTION 71
10th Apr 2023COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
30th Jul 2021NEW REPRESENTATIVE AT IB RECEIVED
30th Apr 2020CHANGE OF OWNER RECEIVED FROM IB
26th Jul 2019NEW REPRESENTATIVE AT IB RECEIVED
24th Aug 2018FINAL DECISION TRANSACTION PROCESSED BY IB
30th Jul 2018FINAL DISPOSITION NOTICE SENT TO IB
30th Jul 2018FINAL DISPOSITION PROCESSED
10th Jul 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10th Apr 2018REGISTERED-PRINCIPAL REGISTER